Search results
Dexcom details plans for over-the-counter CGM as insulin pump firms seek Type 2 coverage
MedTech Dive via Yahoo Finance· 11 hours agoThe company plans to launch Stelo this summer as a 15-day cash-pay product for an undisclosed price....
Earnings call: Zealand Pharma reports solid Q1 results, advances in obesity treatment By...
Investing.com· 5 hours agoCEO Adam Steensberg highlighted the company's satisfaction with its financial performance in the...
'It Was Just Strange': Kyle Richards Confirms Mauricio Umansky Moved Out of $10 Million Marital Home...
RadarOnline.com· 1 day agoRichards seemed somewhat surprised by the move, saying she knew this day would come but was unaware...
Clinicians Call for Easing FDA Warnings on Low-Dose Estrogen
Medscape· 3 days agoCharles Powell, MD, said he sometimes has a hard time persuading patients to start on low-dose...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 9 hours agoCompleted acquisition of Trawsfynydd and concurrent $14 million Capital Raise Excellent pipeline progress, led by candidates for COVID 19, influenza, and oncology programs ...
Earnings call: Plus Therapeutics reveals Q1 2024 financials, clinical progress By Investing.com
Investing.com· 10 hours agoTherapeutics, Inc. (NASDAQ:PSTV) announced its first quarter 2024 financial results and provided...
Cyclacel Pharmaceuticals Inc (CYCC) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
GuruFocus.com via Yahoo Finance· 2 days agoThe company has initiated the Phase 2 proof of concept part of the 065-101 study, focusing on patients with specific chromosomal abnormalities, potentially addressing unmet medical needs. No ...
Atea Pharmaceuticals Inc (AVIR) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ...
GuruFocus.com via Yahoo Finance· 1 day agoThe company reported a robust financial position with $541.5 million in cash, cash equivalents, and marketable securities as of March 31, 2024, extending their financial runway ...
Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
Zacks· 17 hours agoFree Report) reported first-quarter 2024 loss per share of 82 cents, narrower than the Zacks Consensus Estimate of a loss of $1.09. Currently, KOD does not have any approved products in its ...
Ocugen Inc (OCGN) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances Amid ...
GuruFocus.com via Yahoo Finance· 2 days agoResearch and Development Expenses: $6.8 million for Q1 2024, down from $10.2 million in Q1 2023. General and Administrative Expenses: $6.4 million ...